Table 4. Indication for allogeneic stem cell transplantation in acute myeloid leukemia^*.

Risk of recurrence with conventional consolidation depending on selected disease characteristics	Acceptable risk of transplantation-associated mortality for SCT _(e.g.. according to HCT-CI)
Indication for allogeneic SCT in first complete remission
Low risk of recurrence (35–40%). e.g.: t(8;21) with leukocytes <20 gpt/l inv(16)/t(16;16) mutation of npm1 gene without tandem duplication of flt3 gene (molecular) complete remission after first induction	Low (SCT justified only in absence of comorbidities)
Moderate risk of recurrence (50–55%). e.g.: t(8;21) with leukocytes >20 Gpt/L cytogenetically normal (including with loss of X or Y chromosome) Leukocytes <100 gpt/l with complete remission after first induction	Moderate (SCT justified only with low number of comorbidities)
High risk of recurrence (70–80%). e.g.: any good or intermediate cytogenetic risk. but no complete remission after first induction chemotherapy cytogenetically normal with leukocytes >100 Gpt/L any other cytogenetic aberration	High (consider SCT even in presence of comorbidities)
Very high risk of recurrence (>90%). e.g.: monosomal karyotype overexpression of Evi-1 gene	Very high (consider SCT even in presence of comorbidities)
Indication for allogeneic SCT in recurrence
All constellations	According to individual assessment

^*Allogeneic SCT in AML in first complete remission is always an individual decision. There is good evidence particularly for AML with high risk of recurrence. In cases with moderate or low risk of recurrence. assessment of the risks entailed in SCT is of special importance.

AML. acute myeloid leukemia; Evi-1. ectropic viral integration site 1; HCT-CI. hematopoietic cell transplantation-specific comorbidity index; FLT3. Fms-like tyrosine kinase receptor 3; _NPM1. nucleophosmin; SCT. stem cell transplantation